Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/13/2024 | $28.00 | Outperform | Robert W. Baird |
6/6/2024 | $22.00 | Buy | H.C. Wainwright |
11/28/2023 | $20.00 | Overweight | JP Morgan |
11/28/2023 | $20.00 | Buy | Stifel |
11/28/2023 | $19.00 | Outperform | Leerink Partners |
11/28/2023 | $22.00 | Outperform | RBC Capital Mkts |
11/28/2023 | $23.00 | Buy | Chardan Capital Markets |
S-3/A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
S-3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac d
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov
Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00
H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00
JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)